Several other brokerages have also recently commented on AGN. Zacks Investment Research cut Allergan from a hold rating to a sell rating in a research report on Wednesday, October 3rd. ValuEngine raised Allergan from a strong sell rating to a sell rating in a report on Friday, September 21st. TheStreet raised Allergan from a d+ rating to a c rating in a report on Monday, August 20th. Cowen set a $255.00 price target on Allergan and gave the company a buy rating in a report on Wednesday, October 17th. Finally, Cantor Fitzgerald reaffirmed a hold rating and issued a $180.00 price target on shares of Allergan in a report on Friday, September 14th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eighteen have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $210.18.
Shares of Allergan stock traded down $3.06 during midday trading on Wednesday, hitting $165.52. The company had a trading volume of 2,039,730 shares, compared to its average volume of 2,414,899. The company has a market cap of $57.21 billion, a price-to-earnings ratio of 10.12, a PEG ratio of 1.34 and a beta of 1.31. The company has a current ratio of 0.92, a quick ratio of 0.78 and a debt-to-equity ratio of 0.32. Allergan has a 1-year low of $142.81 and a 1-year high of $197.00.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 14th. Investors of record on Tuesday, November 13th will be given a $0.72 dividend. The ex-dividend date of this dividend is Friday, November 9th. This represents a $2.88 annualized dividend and a dividend yield of 1.74%. Allergan’s dividend payout ratio is presently 17.61%.
In related news, Director Christopher J. Coughlin acquired 10,000 shares of the company’s stock in a transaction dated Thursday, September 6th. The shares were bought at an average price of $190.64 per share, for a total transaction of $1,906,400.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Joseph H. Boccuzi acquired 900 shares of the company’s stock in a transaction dated Thursday, August 30th. The shares were bought at an average price of $190.59 per share, for a total transaction of $171,531.00. The disclosure for this purchase can be found here. Insiders own 0.36% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Summit Trail Advisors LLC increased its holdings in shares of Allergan by 13,646.4% during the 1st quarter. Summit Trail Advisors LLC now owns 1,199,371 shares of the company’s stock worth $1,199,000 after acquiring an additional 1,190,646 shares during the last quarter. Thompson Siegel & Walmsley LLC increased its holdings in shares of Allergan by 3,032.4% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 877,740 shares of the company’s stock worth $146,337,000 after acquiring an additional 849,719 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Allergan by 27,066.5% during the 2nd quarter. Renaissance Technologies LLC now owns 787,828 shares of the company’s stock worth $131,347,000 after acquiring an additional 784,928 shares during the last quarter. Sound Shore Management Inc. CT acquired a new position in shares of Allergan during the 3rd quarter worth approximately $140,026,000. Finally, Mainstay Capital Management LLC ADV increased its holdings in shares of Allergan by 13,097.2% during the 2nd quarter. Mainstay Capital Management LLC ADV now owns 675,039 shares of the company’s stock worth $4,288,000 after acquiring an additional 669,924 shares during the last quarter. Institutional investors own 77.55% of the company’s stock.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Featured Story: How accurate is the Rule of 72?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.